Clinical Trials Directory

Trials / Completed

CompletedNCT07306377

H. Pylori Infection and AIP Levels

Helicobacter Pylori Infection as A Potential Risk Factor for Dyslipidemia: Insights From Atherogenic Index of Plasma (AIP)

Status
Completed
Phase
Study type
Observational
Enrollment
300 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Helicobacter pylori is a common bacterial infection of the stomach that can cause ulcers and other digestive problems. Recent studies suggest that this infection may also affect metabolism and blood fats (lipids), which are important for heart health. Changes in lipid levels, such as higher triglycerides and lower "good" cholesterol (HDL), can increase the risk of cardiovascular disease. This study will examine whether H. pylori infection is linked to changes in lipid profiles, especially the Atherogenic Index of Plasma (AIP). AIP is a calculation based on triglycerides and HDL cholesterol that helps predict the risk of heart disease.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTurea breath testParticipants will undergo a urea breath test to confirm H. pylori infection status. Fasting blood samples will be collected to measure triglycerides and HDL cholesterol, and the Atherogenic Index of Plasma (AIP) will be calculated.

Timeline

Start date
2025-01-02
Primary completion
2025-02-18
Completion
2025-08-04
First posted
2025-12-29
Last updated
2025-12-29

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07306377. Inclusion in this directory is not an endorsement.